v3.25.2
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($)
$ in Thousands
Total
Total Stockholders’ Equity attributable to Privia Health Group, Inc.
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2023     118,216,979      
Beginning balance at Dec. 31, 2023 $ 607,389 $ 561,437 $ 1,182 $ 753,869 $ (193,614) $ 45,952
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     461,923      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 475 475 $ 5 470    
Stock-based compensation expense 11,904 11,904   11,904    
Net income 3,056 2,984     2,984 72
Ending balance (in shares) at Mar. 31, 2024     118,678,902      
Ending balance at Mar. 31, 2024 622,824 576,800 $ 1,187 766,243 (190,630) 46,024
Beginning balance (in shares) at Dec. 31, 2023     118,216,979      
Beginning balance at Dec. 31, 2023 607,389 561,437 $ 1,182 753,869 (193,614) 45,952
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 7,699          
Ending balance (in shares) at Jun. 30, 2024     119,479,134      
Ending balance at Jun. 30, 2024 643,607 595,407 $ 1,194 781,376 (187,163) 48,200
Beginning balance (in shares) at Mar. 31, 2024     118,678,902      
Beginning balance at Mar. 31, 2024 622,824 576,800 $ 1,187 766,243 (190,630) 46,024
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     800,232      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 749 749 $ 7 742    
Stock-based compensation expense 14,391 14,391   14,391    
Contributed non-controlling interest 1,000         1,000
Net income 4,643 3,467     3,467 1,176
Ending balance (in shares) at Jun. 30, 2024     119,479,134      
Ending balance at Jun. 30, 2024 $ 643,607 595,407 $ 1,194 781,376 (187,163) 48,200
Beginning balance (in shares) at Dec. 31, 2024 120,309,346   120,309,346      
Beginning balance at Dec. 31, 2024 $ 683,447 635,183 $ 1,203 813,209 (179,229) 48,264
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     1,081,968      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 2,243 2,243 $ 11 2,232    
Stock-based compensation expense 17,790 17,790   17,790    
Net income 6,046 4,220     4,220 1,826
Ending balance (in shares) at Mar. 31, 2025     121,391,314      
Ending balance at Mar. 31, 2025 $ 709,526 659,436 $ 1,214 833,231 (175,009) 50,090
Beginning balance (in shares) at Dec. 31, 2024 120,309,346   120,309,346      
Beginning balance at Dec. 31, 2024 $ 683,447 635,183 $ 1,203 813,209 (179,229) 48,264
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income $ 9,334          
Ending balance (in shares) at Jun. 30, 2025 122,673,254   122,673,254      
Ending balance at Jun. 30, 2025 $ 733,546 682,855 $ 1,227 853,950 (172,322) 50,691
Beginning balance (in shares) at Mar. 31, 2025     121,391,314      
Beginning balance at Mar. 31, 2025 709,526 659,436 $ 1,214 833,231 (175,009) 50,090
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     1,281,940      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 1,883 1,883 $ 13 1,870    
Stock-based compensation expense 18,849 18,849   18,849    
Net income $ 3,288 2,687     2,687 601
Ending balance (in shares) at Jun. 30, 2025 122,673,254   122,673,254      
Ending balance at Jun. 30, 2025 $ 733,546 $ 682,855 $ 1,227 $ 853,950 $ (172,322) $ 50,691